Cancer drug regorafenib gets a second chance in small continuation study

NCT ID NCT06246643

Ongoing Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the same dose they were on before. Researchers will track side effects and any dose changes needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib (Stivarga)
What this could lead to: If successful, this study could show that continuing regorafenib is safe and tolerable for people with solid tumors who already benefit from it.
What could go wrong: This is a very small, early-phase study with only 13 participants, so results may not apply widely. Regorafenib can cause side effects like fatigue, liver issues, and bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID MALIGNANT TUMORS

Contacts and locations

Show contact details

Locations

China Medical University Hospital

Taichung, 404327, Taiwan
Hopital Claude Huriez - Lille

Lille, Hauts-de-France, 59037, France
Hospital Infantil Universitario Nino Jesus | Oncologia Pediatrica

Madrid, 28009, Spain
Hôpital Beaujon - Clichy

Clichy, Île-de-France Region, 92110, France
Hôpital Paul Brousse - Villejuif

Villejuif, Île-de-France Region, 94800, France
Saitama Cancer Center

Kitaadachi, Saitama, 362-0806, Japan
Seoul National University Hospital (SNUH) - Medical Oncology Center

Seoul, Seoul Teugbyeolsi, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.